<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501709</url>
  </required_header>
  <id_info>
    <org_study_id>39-42C</org_study_id>
    <nct_id>NCT00501709</nct_id>
  </id_info>
  <brief_title>Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus</brief_title>
  <official_title>Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic islets are the part of the pancreas that produce insulin and help control the&#xD;
      blood sugar. This study aims to improve islet transplantation as a treatment for Type 1&#xD;
      Diabetes by using a new combination of immunosuppressive drugs that have been successful in&#xD;
      treating other autoimmune diseases and in preventing kidney transplant rejection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of these studies is to assess the efficacy and safety of allogeneic&#xD;
      pancreatic islet transplantation in the treatment of type I diabetes mellitus. A secondary&#xD;
      study objective is to evaluate the efficacy of various immunosuppressive protocols and agents&#xD;
      in preventing autoimmune destruction and rejection of allogeneic islet transplants. A&#xD;
      tertiary objective is to determine the safety and efficacy of allogeneic pancreatic islet&#xD;
      transplantation in patients who have received another organ transplant such as a kidney or&#xD;
      liver.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lnsulin independence</measure>
    <time_frame>monthly</time_frame>
    <description>improved glycemic control</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogenic pancreatic islet transplant using belatacept and raptiva</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept and Raptiva</intervention_name>
    <description>immunosuppressant agent to prevent rejection in transplant recipients</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>immunosuppressant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 Diabetes&#xD;
&#xD;
          -  Metabolic lability/instability characterized by hypoglycemia or ketoacidosis(&gt;2&#xD;
             hospital admissions in the previous year), erratic glucose profiles(MAGE &gt;120mg/dL),&#xD;
             or disruption in lifestyle(danger to life, self or others). Reduced awareness of&#xD;
             hypoglycemia or &gt; 1 episode in the last 1.5 years of severe hypoglycemia.&#xD;
&#xD;
          -  Persistently poor glucose control (as defined by HgbA1c&gt;10% at the end of six months&#xD;
             of intensive management efforts with diabetes care team.&#xD;
&#xD;
          -  Progressive secondary complications as defined by&#xD;
&#xD;
               -  a new diagnosis by an ophthalmologist of proliferative retinopathy or clinically&#xD;
                  significant macular edema or therapy with photocoagulation during the last year;&#xD;
                  or&#xD;
&#xD;
               -  urinary albumin excretion rate &gt;300mg/day but proteinuria &lt;3g/day; or&#xD;
&#xD;
               -  symptomatic autonomic neuropathy (as defined by postural hypotension in the&#xD;
                  setting of euvolemia, gastroparesis or diarrhea attributed to diabetic&#xD;
                  neuropathy, or neuropathic bladder as diagnosed by an urologist)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient weighs more than 80kg or body mass index BMI&gt;28&#xD;
&#xD;
          -  Patient's insulin requirement is &gt;55 Units/day.&#xD;
&#xD;
          -  Current use of immunosuppressive agents.&#xD;
&#xD;
          -  History of malignancy within 10 years (except for adequately treated basal or squamous&#xD;
             cell CA of the skin).&#xD;
&#xD;
          -  Active peptic ulcer disease.&#xD;
&#xD;
          -  Severe unremitting diarrhea or other GI disorders potentially interfering with the&#xD;
             ability to absorb oral medications.&#xD;
&#xD;
          -  Untreated proliferative retinopathy.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Female subjects not post-menopausal or surgically sterile, or not using an acceptable&#xD;
             method or contraception.&#xD;
&#xD;
          -  Active infections.&#xD;
&#xD;
          -  Major ongoing psychiatric illness.&#xD;
&#xD;
          -  Ongoing substance abuse, drug or alcohol; or recent history of noncompliance.&#xD;
&#xD;
          -  Portal hypertension or history of significant liver disease.&#xD;
&#xD;
          -  Lymphopenia (&lt;1000/ul) or leukopenia (&lt;3000 total leukocytes/ul) or an absolute CD4&#xD;
             count &lt;500/ul.&#xD;
&#xD;
          -  Presence or history of panel-reactive anti-HLA antibody &gt;20%.&#xD;
&#xD;
          -  Evidence of acute EBV infection (IgM&gt;IgG) OR no serologic evidence of previous&#xD;
             exposure to EBV (IgG&gt;IgM).&#xD;
&#xD;
          -  Serologic evidence of infection with HIV or HbsAg or HCV Ab positive.&#xD;
&#xD;
          -  Creatinine clearance &lt;60ml/min/m2.&#xD;
&#xD;
          -  Positive lymphocytoxic cross-match using donor lymphocytes and serum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G Stock, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Posselt, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <disposition_first_submitted>April 30, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 6, 2020</disposition_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

